Pharmaceutical drug product development can be an expensive and time-consuming process. Many challenges are faced by pharmaceutical development companies including developing a scaleable, marketable formulation, ensuring safety and efficacy of the
In today's competitive pharmaceutical environment, building and maintaining market share is
paramount. With dwindling pipelines, limited resources and expiring patents, now, more that ever,
combination products are being considered in drug development
The rising complexity of active pharmaceutical ingredients (APIs), combined with the need to curb costs, calls for creative solutions. The use of highly reactive reagents in the synthesis routes offers an important extension of the existing traditional
Aptuit maintains two customized Uhlmann UPS1030ETs to produce state-of-the-art blister packaging in a single integrated process. The equipment provides multiple blister packaging as well as child-resistant kiss-cut perforation and puncture and access
Aptuit's solid-state chemistry team was required to develop a more water-soluble form than the API compound provided by its client. The compound also demonstrated low in vivo concentrations when tested orally in dogs.
After preliminary testing
Aptuit partnered with a small pharmaceutical company to develop its product for an orphan drug for Phase I clinical trials. A simple dry blend in capsule form was developed in 5mg, 20mg and 100mg doses.
Using their accelerated 'SuperMethod',
GP Pharm, the pharmaceutical company of the Lipotec Group, specialises in the research, development, production and marketing of injectable products within the urology, oncology, central nervous system and cardiovascular fields, some of them based
ORPEGEN Peptide Chemicals (OPC) is a leading supplier of amino acids and derivatives for both the pharmaceutical industry and research labs worldwide. ORPEGEN Peptide Chemicals is also a contract manufacturer for active pharmaceutical ingredients (APIs)
Preclinical testing is a crucial element in the process of filing a new chemical entity (NCE). A pharmaceutical company contracted Aptuit to satisfy regulatory demand for their NCE within an aggressive timeline. Aptuit's project manager led the program's
In the highly specialised world of sterile liquid dosage forms, IDT Biologika is a contract manufacturing organisation with the experience, the capability and the commitment to excellence to offer you a strategic advantage in your commercialisation
Ropack's Paul Dupont explains how growing trends in the consumer healthcare industry signal promising market opportunities for leading nutraceutical and pharmaceutical companies.
Download this free whitepaper to find out more.
Gesellschaft für Micronisierung
(GfM) is an innovative, owner-managed company. Our employees – all specialists in their fields – will micronise
and refine your active pharmaceutical ingredients, excipients and carrier substances (standard micronisation
and
With B. Braun you profit from the expertise of one of the world's leading companies in international healthcare. Whatever you need to realise your idea, partnering with B Braun gives you access to complete project management
capabilities.
The
Taking an original concept from the bench through to the production of GMP biopharmaceutical material for clinical trials is challenging. The world class expertise of the Health Protection Agency's centre at Porton Down in process development, scale-up
The past decade has seen enormous activity in research on drug delivery and targeting using emulsions. Emulsions are now not only well established as drug delivery systems of poorly water-soluble drugs, but are also used increasingly as a means of
With development times measured in years, increasing
costs represent a major challenge confronting pharmaceutical
and biotechnology companies. As a result, reducing time-to-market is an essential component in any business strategy, particularly when
Contract manufacturing became popular in many
industries during the 1990s as a way to counter rising
costs and to reinvestment. The pharmaceutical industry
has been slow to adopt this practice because of its
absolute need for secrecy.
However,
Cangene provides small-scale production for clinical trials and large-scale manufacturing to support commercial launch.
